ProCE Banner Activity

Combination Ruxolitinib + Sonidegib in Myelofibrosis

Slideset Download
Conference Coverage
Combination therapy was well tolerated and showed preliminary efficacy similar to single-agent ruxolitinib.

Released: December 10, 2015

Expiration: December 08, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen